Table 1.
Change in primary efficacy variables from baseline to weeks 21 and 34, showing means ± standard deviation.
| Absolute change from baseline | ||||
|---|---|---|---|---|
| Bendrofluazide (n) | Doxazosin (n) | Adjusted treatment difference (95% CI) | P-value | |
| Glucose (mmol/l)a | ||||
| Baseline | 5.66±1.814 (81) | 6.08±1.830 (78) | ||
| Week 21 | 0.82±2.254 (62) | −0.07±2.015 (57) | −0.14 (−0.26 to −0.01) | 0.029 |
| Week 34 | 1.02±2.798 (44) | −0.22±1.545 (49) | −0.17 (−0.30 to −0.03) | 0.015 |
| Total cholesterol (mmol/l) | ||||
| Baseline | 5.64±0.874 (81) | 5.30±0.990 (78) | ||
| Week 21 | 0.00±0.610 (64) | −0.11±0.631 (60) | −0.22 (−0.43 to 0.00) | 0.048 |
| Week 34 | −0.05±0.583 (44) | −0.26±0.526 (49) | −0.21 (−0.44 to 0.02) | 0.069 |
a
Endpoints for glucose were log-transformed before analysis and the adjusted treatment differences are presented on a logscale.